Faculty profile

Sylvain Baruchel

Back to faculty

ProfessorDepartment of PaediatricsUniversity of Toronto

Sylvain Baruchel

Professor

Department of Paediatrics

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
3 publications in the last five years, latest in 2026.
Principal investigator on 2 research grants (2 CIHR), most recently in 2011.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

831

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Metabolomic investigation of cisplatin‐induced acute kidney injury in paediatric cancer patients
British Journal of Clinical Pharmacology · 2026
Translating regenerative medicine therapies in neonatal necrotizing enterocolitis
Pediatric Research · 2024
Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial
Cancers · 2022

All 23 publications

Latest funding

Taking the "idiopathic" out of scoliosis: from biology and genetics to non-invasive therapies
CIHR · 2018 · Co-investigator
$3,541,811
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team)
CIHR · 2011 · Principal investigator
$4,063,033
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team)
CIHR · 2010 · Principal investigator
$5,000

All 4 grants and awards

23 publications.

Metabolomic investigation of cisplatin‐induced acute kidney injury in paediatric cancer patients

Lim YJ, Thachil A, McMahon K, Tsuyuki RT, Rassekh SR, Mitchell LG, Devarajan P, Mammen C, Carleton BC, Cuvelier GDE

British Journal of Clinical Pharmacology2026Open Access

DOI: 10.1002/bcp.70587

Translating regenerative medicine therapies in neonatal necrotizing enterocolitis

Ganji N, Kalish B, Offringa M, Li B, Anderson J, Baruchel S, Blakely M, De Coppi P, Eaton S, Gauda E

Pediatric Research20249 citationsOpen Access

DOI: 10.1038/s41390-024-03236-x

Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial

Arif Manji, Yvan Samson, Rebecca J. Deyell, Donna Lynn Johnston, Victor Anthony Lewis, Alexandra Patricia Zorzi, Jason N. Berman, Kathy Brodeur‐Robb, Ellen M. Morrison, Lynn Kee, Sushil Kumar, Sylvain Baruchel, James A. Whitlock, Daniel A. Morgenstern

Cancers202213 citationsOpen Access

DOI: 10.3390/cancers14122985 PMID: 35740650

Phase I dose-finding study for melatonin in pediatric oncology patients with relapsed solid tumors.

Johnston DL, Zupanec S, Nicksy D, Morgenstern D, Narendran A, Deyell RJ, Samson Y, Wu B, Baruchel S

Pediatric blood & cancer20198 citationsSenior author

DOI: 10.1002/pbc.27676 PMID: 30786157

Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218

Deyell RJ, Wu B, Rassekh SR, Tu D, Samson Y, Fleming A, Bouffet E, Sun X, Powers J, Seymour L

Pediatric Blood and Cancer20196 citations

DOI: 10.1002/pbc.27540

Population pharmacokinetics of trabectedin in adolescent patients with cancer.

Poggesi I, Valenzuela B, Ouellet D, Gonzalez M, Hillewaert V, Baruchel S, Fox E, Perez-Ruixo JJ

Cancer chemotherapy and pharmacology2019

DOI: 10.1007/s00280-019-03899-y PMID: 31286189

Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma.

Alexander N, Vali R, Ahmadzadehfar H, Shammas A, Baruchel S

Current radiopharmaceuticals2018Senior author

DOI: 10.2174/1874471011666171215093112 PMID: 29243585

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models.

Kumar S, Sun JD, Zhang L, Mokhtari RB, Wu B, Meng F, Liu Q, Bhupathi D, Wang Y, Yeger H, Hart C, Baruchel S

Translational oncology2018Senior author

DOI: 10.1016/j.tranon.2018.05.004 PMID: 29803017

Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models.

Zhang L, Wu B, Baruchel S

Translational oncology2017Senior author

DOI: 10.1016/j.tranon.2017.04.008 PMID: 28666189

Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.

Zhang L, Marrano P, Wu B, Kumar S, Thorner P, Baruchel S

Clinical cancer research : an official journal of the American Association for Cancer Research2016Senior author

DOI: 10.1158/1078-0432.ccr-15-1853 PMID: 26719428

Taking the "idiopathic" out of scoliosis: from biology and genetics to non-invasive therapies

Co-investigatorCIHR2018Foundation Grant

Principal investigators: Ciruna, Brian G

Keywords: Cerebrospinal Fluid; Csf-Contacting Neurons; Developmental Genetics; Idiopathic Scoliosis; Motile Cilia; Neuroinflammation; Pre-Clinical Models; Small Molecule Screens; Whole Genome Sequencing; Zebrafish Models Of Human Disease

$3,541,811

Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team)

Principal investigatorCIHR2011Team Grant: Childhood Cancer - Late Effects of Treatment

Principal investigators: Schultz, Kirk R; Baruchel, Sylvain; Mcbride, Mary L; Mitchell, Lesley G; Rassekh, Shahrad R; Tsuyuki, Ross T; Zappitelli, Michael

Keywords: Biomarkers; Chronic Graft Versus Host Disease; Clinical Interventions; Long Term Effects Of Cancer Therapy; Nephrotoxicity; Oto-Toxicity; Thrombosis

$4,063,033

Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team)

Principal investigatorCIHR2010Team Grant: Childhood Cancer - Late Effects of Treatment -LOI

Principal investigators: Schultz, Kirk R; Baruchel, Sylvain; Blydt-Hansen, Tom; Brandao, Leonardo R; Broady, Raewyn; Cuvelier, Geoff; Lee, Agnes Yuet Ying; Mcbride, Mary L; Mitchell, Lesley G; Pinsk, Maury N; Rassekh, Shahrad R; Ross, Colin J; Spavor, Maria; Tsuyuki, Ross T; Zappitelli, Michael

Keywords: Biomarkers; Chronic Graft-Versus-Host Disease; Clinical Interventions; Long Term Effects Of Cancer Therapy; Nephrotoxicity; Oto-Toxicity; Thrombosis

$5,000

The Toronto Angiogenesis Research Centre.

Co-investigatorCFI2002Innovation Fund: Innovation Fund (1999-2005)

Principal investigators: Kerbel, Robert

Keywords: Angiogenesis, Proteomics, Vascular Imaging, Transgenic Mice, Animal Models, Vascular Development, Cancer, Anti-Angiogenic Therapy, Pharmacology

$4,652,062

From public funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998 with their latest competition results, the Canada Foundation for Innovation, Genome Canada, the Canadian Space Agency, Canada Research Chairs, the Fonds de recherche du Québec, Ontario research funding, Michael Smith Health Research BC, the Canadian Cancer Society, Heart & Stroke and Brain Canada.

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Sylvain Baruchel

Research

Latest papers

Latest funding

Metabolomic investigation of cisplatin‐induced acute kidney injury in paediatric cancer patients

Translating regenerative medicine therapies in neonatal necrotizing enterocolitis

Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial

Phase I dose-finding study for melatonin in pediatric oncology patients with relapsed solid tumors.

Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218

Population pharmacokinetics of trabectedin in adolescent patients with cancer.

Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma.

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models.

Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models.

Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.

Taking the "idiopathic" out of scoliosis: from biology and genetics to non-invasive therapies

Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team)

Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team)

The Toronto Angiogenesis Research Centre.

Frequent collaborators

Daniel Morgenstern

Meredith Irwin

Rebecca Deyell

Herman Yeger

Uri Tabori

Adam Fleming

Cynthia Hawkins

Eric Bouffet

Donna Johnston

Ute Bartels

David Malkin

Paul Gibson

Nirit Bernhard

Elena Pope

Raveena Ramphal

Shahrad Rassekh

Mathieu Lemaire

Augusto Zani

James Whitlock

Brian Kalish

Anna Heath

Lesley Seymour